Dr. Mainga Hamaluba
Head Of Clinical Research
Collaborations
Videos
Bio
Mainga Hamaluba MBChB MD FRCPCH Head of Clinical Research. Mainga is a paediatrician and works on clinical trials of vaccines, human infections studies and neonatal care. She is Principal Investigator (PI) and lead of the R21 clinical development programme in Kenya which includes the first evaluation of R21 in Africa (Phase 1b and the ongoing phase 3 trials). This is complemented by a vaccine efficacy Human Infection Study where she is Co-PI. Furthermore, she is PI for a phase 1/2 (First-In-Human and phase 2 trial of the leading tetravalent candidate shigella vaccine); sponsored by LimmaTech Biologics Ag. She also has clinical oversight of the broad portfolio of KWTRP team Human Infection Study platforms for malaria and shigella. These complementary programs continue to accelerate the clinical development of malaria and shigella vaccines.
See moreCurrent Work
Her current research focus is part of the Calestous Juma Fellowship funded by the Bill and Melinda Gates Foundation. This fellowship supports setting up a platform trial of neonatal interventions in coastal Kenya with a plan to expand this regionally to reduce neonatal mortality. She is currently supervising 1 PhD student working on snakebite research and has co-supervised MSc and PGDip studentships. She is currently PI or Co-PI of 9 clinical trials.
Recent publications
Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.
Gallagher, K. E., Lucinde, R., Bottomley, C., Kaniu, M., Suaad, B., Mutahi, M., Mwalekwa, L., Ragab, S., Twi-Yeboah, L., Berkley, J. A., Hamaluba, M., Karani, A., Shangala, J., Otiende, M., Gardiner, E., Mugo, D., Smith, P. G., Tabu, C., Were, F., Goldblatt, D., Scott, J. A. G.
N Engl J Med, (2024). :
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling, W. H. K., Mukaka, M., Callery, J. J., Llewelyn, M. J., Cruz, C. V., Dhorda, M., Ngernseng, T., Waithira, N., Ekkapongpisit, M., Watson, J. A., Chandna, A., Nelwan, E. J., Hamers, R. L., Etyang, A., Beg, M. A., Sow, S., Yavo, W., Allabi, A. C., Basnyat, B., Sharma, S. K., Amofa-Sekyi, M., Yonga, P., Adler, A., Yuentrakul, P., Cope, T., Thaipadungpanit, J., Rienpradub, P., Imwong, M., Abdad, M. Y., Blacksell, S. D., Tarning, J., Goudjo, F. F., Dossou, A. D., Konaté-Touré, A., Assi, S. B., Ouffoué, K., Nasronudin, N., Rachman, B. E., Romadhon, P. Z., Dewanto, D. D., Heryana, M. O., Novi, T., Pasaribu, A. P., Mutiara, M., Nasution, M. P. R., Khairunnisa, K., Dalimunthe, F. A., Airlangga, E., Fahrezzy, A., Subronto, Y., Ananda, N. R., Rahardjani, M., Rimainar, A., Lucinde, R. K., Timbwa, M., Onyango, O. E., Agutu, C., Akech, S., Hamaluba, M., Kipyego, J., Ngachi, O., Haidara, F. C., Traoré, O. Y., Diarra, F., Khanal, B., Dahal, P., Shrestha, S., Rijal, S., Kabore, Y., Adehossi, E., Guindo, O., Qamar, F. N., Kazi, A. M., Woodrow, C. J., Laird, S., Cheeba, M., Ayles, H., Cheah, P. Y., Taylor, W. R. J., Batty, E. M., Chotivanich, K., Pukrittayakamee, S., Phumratanaprapin, W., von Seidlein, L., Dondorp, A., Day, N. P. J., White, N. J.
PLoS Med, (2024). 21:e1004428
SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART).
Maitland, K., Hamaluba, M., Obonyo, N., Oguda, E., Mogoka, C., Williams, T. N., Chaponda, M., Miti, S., Kamavu, L. K., Jonathan Gwasupika, J., Connon, R., Gibb, D. M., Dondorp, A., Day, N., White, N., Walker, A. S., George, E. C.
Wellcome Open Res, (2023). 8:484
A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial).
Maitland, K., Obonyo, N., Hamaluba, M., Ogoda, E., Mogaka, C., Williams, T. N., Newton, C., Kariuki, S. M., Gibb, D. M., Walker, A. S., Connon, R., George, E. C.
Wellcome Open Res, (2024). 9:281
Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.
Nkumama, I. N., Ogwang, R., Odera, D., Musasia, F., Mwai, K., Nyamako, L., Murungi, L., Tuju, J., Fürle, K., Rosenkranz, M., Kimathi, R., Njuguna, P., Hamaluba, M., Kapulu, M. C., Frank, R., Osier, F. H. A.
Immunity, (2024). 57:1215-1224
Dr. Mainga Hamaluba
Head Of Clinical Research
Biography
Mainga Hamaluba MBChB MD FRCPCH Head of Clinical Research. Mainga is a paediatrician and works on clinical trials of vaccines, human infections studies and neonatal care. She is Principal Investigator (PI) and lead of the R21 clinical development programme in Kenya which includes the first evaluation of R21 in Africa (Phase 1b and the ongoing phase 3 trials). This is complemented by a vaccine efficacy Human Infection Study where she is Co-PI. Furthermore, she is PI for a phase 1/2 (First-In-Human and phase 2 trial of the leading tetravalent candidate shigella vaccine); sponsored by LimmaTech Biologics Ag. She also has clinical oversight of the broad portfolio of KWTRP team Human Infection Study platforms for malaria and shigella. These complementary programs continue to accelerate the clinical development of malaria and shigella vaccines.
See moreCurrent Work
Her current research focus is part of the Calestous Juma Fellowship funded by the Bill and Melinda Gates Foundation. This fellowship supports setting up a platform trial of neonatal interventions in coastal Kenya with a plan to expand this regionally to reduce neonatal mortality. She is currently supervising 1 PhD student working on snakebite research and has co-supervised MSc and PGDip studentships. She is currently PI or Co-PI of 9 clinical trials.
Collaborations
Project Research
No active details yet
Videos
Fractional Doses of Pneumococcal Conjugate Vaccine - A Noninferiority Trial.
Gallagher, K. E., Lucinde, R., Bottomley, C., Kaniu, M., Suaad, B., Mutahi, M., Mwalekwa, L., Ragab, S., Twi-Yeboah, L., Berkley, J. A., Hamaluba, M., Karani, A., Shangala, J., Otiende, M., Gardiner, E., Mugo, D., Smith, P. G., Tabu, C., Were, F., Goldblatt, D., Scott, J. A. G.
N Engl J Med, (2024). :
Evaluation of hydroxychloroquine or chloroquine for the prevention of COVID-19 (COPCOV): A double-blind, randomised, placebo-controlled trial.
Schilling, W. H. K., Mukaka, M., Callery, J. J., Llewelyn, M. J., Cruz, C. V., Dhorda, M., Ngernseng, T., Waithira, N., Ekkapongpisit, M., Watson, J. A., Chandna, A., Nelwan, E. J., Hamers, R. L., Etyang, A., Beg, M. A., Sow, S., Yavo, W., Allabi, A. C., Basnyat, B., Sharma, S. K., Amofa-Sekyi, M., Yonga, P., Adler, A., Yuentrakul, P., Cope, T., Thaipadungpanit, J., Rienpradub, P., Imwong, M., Abdad, M. Y., Blacksell, S. D., Tarning, J., Goudjo, F. F., Dossou, A. D., Konaté-Touré, A., Assi, S. B., Ouffoué, K., Nasronudin, N., Rachman, B. E., Romadhon, P. Z., Dewanto, D. D., Heryana, M. O., Novi, T., Pasaribu, A. P., Mutiara, M., Nasution, M. P. R., Khairunnisa, K., Dalimunthe, F. A., Airlangga, E., Fahrezzy, A., Subronto, Y., Ananda, N. R., Rahardjani, M., Rimainar, A., Lucinde, R. K., Timbwa, M., Onyango, O. E., Agutu, C., Akech, S., Hamaluba, M., Kipyego, J., Ngachi, O., Haidara, F. C., Traoré, O. Y., Diarra, F., Khanal, B., Dahal, P., Shrestha, S., Rijal, S., Kabore, Y., Adehossi, E., Guindo, O., Qamar, F. N., Kazi, A. M., Woodrow, C. J., Laird, S., Cheeba, M., Ayles, H., Cheah, P. Y., Taylor, W. R. J., Batty, E. M., Chotivanich, K., Pukrittayakamee, S., Phumratanaprapin, W., von Seidlein, L., Dondorp, A., Day, N. P. J., White, N. J.
PLoS Med, (2024). 21:e1004428
SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART).
Maitland, K., Hamaluba, M., Obonyo, N., Oguda, E., Mogoka, C., Williams, T. N., Chaponda, M., Miti, S., Kamavu, L. K., Jonathan Gwasupika, J., Connon, R., Gibb, D. M., Dondorp, A., Day, N., White, N., Walker, A. S., George, E. C.
Wellcome Open Res, (2023). 8:484
A Phase I trial of Non-invasive Ventilation and seizure prophylaxis with levetiracetam In Children with Cerebral Malaria Trial (NOVICE-M Trial).
Maitland, K., Obonyo, N., Hamaluba, M., Ogoda, E., Mogaka, C., Williams, T. N., Newton, C., Kariuki, S. M., Gibb, D. M., Walker, A. S., Connon, R., George, E. C.
Wellcome Open Res, (2024). 9:281
Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge.
Nkumama, I. N., Ogwang, R., Odera, D., Musasia, F., Mwai, K., Nyamako, L., Murungi, L., Tuju, J., Fürle, K., Rosenkranz, M., Kimathi, R., Njuguna, P., Hamaluba, M., Kapulu, M. C., Frank, R., Osier, F. H. A.
Immunity, (2024). 57:1215-1224
Dr. Mainga Hamaluba 9
Head Of Clinical Research
Biography
Mainga Hamaluba MBChB MD FRCPCH Head of Clinical Research. Mainga is a paediatrician and works on clinical trials of vaccines, human infections studies and neonatal care. She is Principal Investigator (PI) and lead of the R21 clinical development programme in Kenya which includes the first evaluation of R21 in Africa (Phase 1b and the ongoing phase 3 trials). This is complemented by a vaccine efficacy Human Infection Study where she is Co-PI. Furthermore, she is PI for a phase 1/2 (First-In-Human and phase 2 trial of the leading tetravalent candidate shigella vaccine); sponsored by LimmaTech Biologics Ag. She also has clinical oversight of the broad portfolio of KWTRP team Human Infection Study platforms for malaria and shigella. These complementary programs continue to accelerate the clinical development of malaria and shigella vaccines.